Simulations Plus Inc (SLP) - Total Assets
Based on the latest financial reports, Simulations Plus Inc (SLP) holds total assets worth $146.48 Million USD as of February 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Simulations Plus Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Simulations Plus Inc - Total Assets Trend (1996–2025)
This chart illustrates how Simulations Plus Inc's total assets have evolved over time, based on quarterly financial data. Explore Simulations Plus Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Simulations Plus Inc - Asset Composition Analysis
Current Asset Composition (August 2025)
Simulations Plus Inc's total assets of $146.48 Million consist of 39.1% current assets and 60.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.4% |
| Accounts Receivable | $14.62 Million | 11.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $29.21 Million | 22.1% |
| Goodwill | $43.72 Million | 33.1% |
Asset Composition Trend (1996–2025)
This chart illustrates how Simulations Plus Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SLP market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Simulations Plus Inc's current assets represent 39.1% of total assets in 2025, a decrease from 60.0% in 1996.
- Cash Position: Cash and equivalents constituted 23.4% of total assets in 2025, up from 20.0% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 55.0% of total assets, an increase from 0.0% in 1996.
- Asset Diversification: The largest asset category is goodwill at 33.1% of total assets.
Simulations Plus Inc Competitors by Total Assets
Key competitors of Simulations Plus Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Waystar Holding Corp. Common Stock
NASDAQ:WAY
|
USA | $5.84 Billion |
|
Oneview Healthcare Plc
AU:ONE
|
Australia | AU$15.49 Million |
|
Forian Inc
NASDAQ:FORA
|
USA | $44.13 Million |
|
CardioComm Solutions Inc.
V:EKG
|
Canada | CA$256.24K |
|
Kovo Healthtech Corp
V:KOVO
|
Canada | CA$6.64 Million |
|
NexgenRX Inc.
V:NXG
|
Canada | CA$39.20 Million |
|
Intrasense
PA:ALINS
|
France | €7.99 Million |
|
FEEDBACK PLC LS-5
F:GZM0
|
Germany | €4.86 Million |
Simulations Plus Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.47 | 4.37 | 18.90 |
| Quick Ratio | 5.47 | 4.37 | 18.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $55.22 Million | $36.02 Million | $131.36 Million |
Simulations Plus Inc - Advanced Valuation Insights
This section examines the relationship between Simulations Plus Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.42 |
| Latest Market Cap to Assets Ratio | 2.45 |
| Asset Growth Rate (YoY) | -36.5% |
| Total Assets | $131.94 Million |
| Market Capitalization | $323.49 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Simulations Plus Inc's assets at a significant premium (2.45x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Simulations Plus Inc's assets decreased by 36.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Simulations Plus Inc (1996–2025)
The table below shows the annual total assets of Simulations Plus Inc from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-08-31 | $131.94 Million | -36.46% |
| 2024-08-31 | $207.64 Million | +7.78% |
| 2023-08-31 | $192.64 Million | +1.12% |
| 2022-08-31 | $190.50 Million | +4.89% |
| 2021-08-31 | $181.61 Million | +6.95% |
| 2020-08-31 | $169.82 Million | +268.41% |
| 2019-08-31 | $46.09 Million | +4.41% |
| 2018-08-31 | $44.15 Million | +14.64% |
| 2017-08-31 | $38.51 Million | +38.46% |
| 2016-08-31 | $27.81 Million | +1.72% |
| 2015-08-31 | $27.34 Million | +30.33% |
| 2014-08-31 | $20.98 Million | +30.61% |
| 2013-08-31 | $16.06 Million | -7.40% |
| 2012-08-31 | $17.35 Million | +9.32% |
| 2011-08-31 | $15.87 Million | +8.23% |
| 2010-08-31 | $14.66 Million | +18.58% |
| 2009-08-31 | $12.36 Million | +6.49% |
| 2008-08-31 | $11.61 Million | +24.32% |
| 2007-08-31 | $9.34 Million | +29.69% |
| 2006-08-31 | $7.20 Million | +18.94% |
| 2005-08-31 | $6.05 Million | +14.09% |
| 2004-08-31 | $5.31 Million | +33.74% |
| 2003-08-31 | $3.97 Million | +150.16% |
| 2002-08-31 | $1.59 Million | +26.15% |
| 2001-08-31 | $1.26 Million | -14.23% |
| 2000-08-31 | $1.47 Million | -9.02% |
| 1999-08-31 | $1.61 Million | -19.87% |
| 1998-08-31 | $2.01 Million | -46.77% |
| 1997-08-31 | $3.78 Million | +277.77% |
| 1996-08-31 | $1.00 Million | -- |
About Simulations Plus Inc
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans… Read more